Ara
Toplam kayıt 3, listelenen: 1-3
Outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical treatment
(Elsevier Science Inc, 2017)
...
Clinicopathological factors in non-small cell lung cancer patients with bone metastases
(Elsevier Science, 2015)
…
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
(Springer, 2022)
Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ...